首页> 外文期刊>Leukemia Research Reports >An ETV6-ABL1 fusion in a patient with chronic myeloproliferative neoplasm: Initial response to Imatinib followed by rapid transformation into ALL
【24h】

An ETV6-ABL1 fusion in a patient with chronic myeloproliferative neoplasm: Initial response to Imatinib followed by rapid transformation into ALL

机译:ETV6-ABL1融合在患有慢性骨髓增生性肿瘤的患者中:对伊马替尼的初始反应,然后迅速转化为ALL

获取原文
       

摘要

We report the case of a 26 year-old patient presenting with a persistent leukocytosis and CML-like marrow but no evidence of a BCR/ABL1 fusion. Molecular cytogenetics revealed that a portion of the ETV6 locus was inserted into the ABL1 locus. An ETV6/ABL1 fusion transcript could subsequently be confirmed. The patient was started on imatinib and went into complete cytomorphological remission. QRT-PCR measurements showed a 4 log reduction of the ETV6/ABL1 fusion. 15 months later, the disease transformed into ALL and the patient expired. Thus, an ETV6/ABL1 fusion positive MPN has the potential to transform very rapidly into ALL.
机译:我们报告一例26岁的病人,表现为持续性白细胞增多和CML样骨髓,但没有BCR / ABL1融合的证据。分子细胞遗传学揭示了ETV6基因座的一部分已插入ABL1基因座。随后可以确认ETV6 / ABL1融合转录本。患者开始接受伊马替尼治疗,并完全缓解了细胞形态。 QRT-PCR测量显示ETV6 / ABL1融合蛋白减少了4 log。 15个月后,疾病转变为ALL,患者死亡。因此,ETV6 / ABL1融合阳性MPN有潜力非常迅速地转变为ALL。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号